S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Instantly Find Hidden Trade Opportunities (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Why Your IRA Could Crash on June 16th (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Why Your IRA Could Crash on June 16th (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Instantly Find Hidden Trade Opportunities (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Why Your IRA Could Crash on June 16th (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Why Your IRA Could Crash on June 16th (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Instantly Find Hidden Trade Opportunities (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Why Your IRA Could Crash on June 16th (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Why Your IRA Could Crash on June 16th (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Instantly Find Hidden Trade Opportunities (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Why Your IRA Could Crash on June 16th (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Why Your IRA Could Crash on June 16th (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
NASDAQ:IOBT

IO Biotech (IOBT) Stock Forecast, Price & News

$2.00
-0.02 (-0.99%)
(As of 06/5/2023 ET)
Compare
Today's Range
$1.96
$2.03
50-Day Range
$1.80
$2.15
52-Week Range
$1.72
$5.76
Volume
7,374 shs
Average Volume
52,448 shs
Market Capitalization
$57.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

IO Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
448.6% Upside
$11.00 Price Target
Short Interest
Bearish
1.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.83mentions of IO Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$58,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.74) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

683rd out of 986 stocks

Pharmaceutical Preparations Industry

331st out of 483 stocks


IOBT stock logo

About IO Biotech (NASDAQ:IOBT) Stock

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Receive IOBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter.

IOBT Stock News Headlines

Analyzing IO Biotech (IOBT) and The Competition
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Jefferies Reaffirms Their Buy Rating on IO Biotech (IOBT)
IO Biotech (NASDAQ:IOBT) Price Target Raised to $11.00
H.C. Wainwright Reaffirms Their Buy Rating on IO Biotech (IOBT)
IO Biotech GAAP EPS of -$0.59 beats by $0.09
IO Biotech Announces 2023 First-Quarter Results
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
IO Biotech (IOBT) vs. Its Competitors Head-To-Head Survey
IO Biotech Inc.
Morgan Stanley Reaffirms Their Buy Rating on IO Biotech (IOBT)
IO Biotech Provides Business Update
IO Biotech Announces Third Quarter Results for 2022
See More Headlines

IOBT Price History

IOBT Company Calendar

Last Earnings
3/14/2023
Today
6/05/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOBT
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+447.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-71,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.82 per share

Miscellaneous

Free Float
27,806,000
Market Cap
$57.92 million
Optionable
Not Optionable
Beta
-0.69

Key Executives

  • Dr. Mai-Britt Zocca Ph.D. (Age 55)
    Founder, Pres, CEO, Principal Financial Officer & Director
    Comp: $514.12k
  • Dr. Muhammad Al-Hajj Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $486.63k
  • Dr. Eva Ehrnrooth M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $443.5k
  • Prof. Inge Marie Svane M.D.
    Ph.D., Founder & Clinical Advisor
  • Prof. Mads Hald Andersen Ph.D.
    Founder & Scientific Advisor
  • Anders Ljungqvist
    Founder
  • Prof. Per Thor Straten
    Founder
  • Ms. Amy B. Sullivan
    Chief Financial Officer
  • Mr. Brian Burkavage (Age 39)
    VP of Fin. & Chief Accounting Officer
  • Mr. Mikkel Dybkjær (Age 50)
    VP of Corp. Fin.













IOBT Stock - Frequently Asked Questions

Should I buy or sell IO Biotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares.
View IOBT analyst ratings
or view top-rated stocks.

What is IO Biotech's stock price forecast for 2023?

2 equities research analysts have issued 12-month target prices for IO Biotech's shares. Their IOBT share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 447.3% from the stock's current price.
View analysts price targets for IOBT
or view top-rated stocks among Wall Street analysts.

How have IOBT shares performed in 2023?

IO Biotech's stock was trading at $2.30 at the beginning of 2023. Since then, IOBT stock has decreased by 12.6% and is now trading at $2.01.
View the best growth stocks for 2023 here
.

When is IO Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our IOBT earnings forecast
.

How were IO Biotech's earnings last quarter?

IO Biotech, Inc. (NASDAQ:IOBT) announced its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.12.

When did IO Biotech IPO?

(IOBT) raised $111 million in an initial public offering on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share.

What is IO Biotech's stock symbol?

IO Biotech trades on the NASDAQ under the ticker symbol "IOBT."

Who are IO Biotech's major shareholders?

IO Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%).
View institutional ownership trends
.

How do I buy shares of IO Biotech?

Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IO Biotech's stock price today?

One share of IOBT stock can currently be purchased for approximately $2.01.

How much money does IO Biotech make?

IO Biotech (NASDAQ:IOBT) has a market capitalization of $57.92 million. The company earns $-71,460,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

How can I contact IO Biotech?

The official website for the company is www.iobiotech.com. The company can be reached via phone at 45-7070-2980.

This page (NASDAQ:IOBT) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -